Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

The arrival of the Wegovy pill (semaglutide), the first oral GLP-1 drug approved to treat obesity, means freedom of choice: Adults who are looking to lose weight and have at least one weight-related ...

At this time, MSA Power Funds LLC's assessment results in a Below Average Parent rating. In its two-year history as a firm, there has been little evidence to suggest MSA Power Funds LLC is a superior ...

The likes of Nvidia, AMD, and Broadcom have joined forces to form an industry consortium aimed at aligning open specifications for optical interconnects for scale-up. The Optical Compute ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Peptides have become a buzzy wellness trend, promoted ...

People who reach a healthy weight and improve their metabolic health on GLP-1 medications are typically told they’ll need to maintain a weekly dose indefinitely to keep the weight off. But emerging ...

With 2026 now in full swing, many are turning their attention to GLP-1 weight-loss medications like Mounjaro, either having started treatment or seriously considering it. However, a prominent expert ...

Meaghan is an editor and writer who also has experience practicing holistic medicine as an acupuncturist and herbalist. She’s passionate about helping individuals live full, healthy and happy lives at ...